转移性结直肠癌免疫检查点抑制剂后的化疗疗效
该回顾性研究评估了29例转移性结直肠癌患者(86%为MSS肿瘤)在免疫检查点抑制剂(ICI)失败后接受化疗(CAICI)的疗效。客观缓解率为19%,疾病控制率62%,中位无进展生存期3.8个月,中位总生存期8.0个月。提示ICI后化疗可能增强细胞毒效应,但需前瞻性验证。
要点
- ICI后化疗在MSS mCRC中客观缓解率19%,疾病控制率62%。
- 中位PFS 3.8个月,中位OS 8.0个月。
- ICI可能作为肿瘤细胞和微环境的调节剂,值得进一步研究。
核心结论
- ICI后化疗可能增强细胞毒效应,即使在免疫难治性MSS mCRC中也是如此。
- 小队列结果需在独立前瞻性队列中验证。
研究设计与样本
- 回顾性评估2014至2018年间29例转移性结直肠癌患者ICI失败后接受化疗。
- ICI方案包括抗PD(L)1单药或联合治疗。
- 主要终点为客观缓解率,次要终点为PFS和OS。
主要发现
- 部分缓解4例(19%),疾病稳定9例(43%),疾病控制率62%。
- 中位PFS为3.8个月(95%CI 1.5-5.4),中位OS为8.0个月(95%CI 4.2-14.0)。
关键数值与推荐
- MSS肿瘤27例(86%),既往治疗线数中位4线(范围2-7)。
- 化疗方案包括TAS-102(14例)、FOLFIRI(6例)、FOLFOX(4例)、瑞戈非尼(3例)和卡铂(1例BRCA突变患者)。
临床怎么用
- 对于ICI失败的MSS mCRC患者,后续化疗仍可考虑,但需注意证据来自小样本回顾性研究。
局限性
- 样本量小(29例),回顾性设计。
- 结果需独立前瞻性队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Although ICIs have failed to demonstrate antitumour activity in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), little is known about CT effect after ICIs. We aimed to assess whether sequential ICIs followed by CT may be an alternative therapeutic approach in a population of pts with mCRC. MATERIAL AND METHODS: We retrospectively assessed CT after ICI (CAICI) failure in pts with mCRC. The ICI regimen consisted of anti-PD(L)1 alone or in combination. The primary end-point was objective response rate. Progression-free survival (PFS) and overall survival (OS) were secondary end-points. RESULTS: Between 2014 and 2018, 29 pts with mCRC received CAICI (MSS tumours, 27 pts [86%]). The median number of previous lines was 4 (range, 2-7). Regimens included TAS-102 (n = 14), FOLFIRI (irinotecan, leucovorin, and fluorouracil; n = 6) or FOLFOX (oxaliplatin, leucovorin, and fluorouracil; n = 4), regorafenib (n = 3) and carboplatin (1 pt with BRCA mutation). Partial response and stable disease were observed in 4 (19%) and 9 (43%) pts, respectively (disease control rate, 62%). The median PFS and OS were 3.8 months (95% confidence interval [CI] = 1.5-5.4) and 8.0 months (95% CI = 4.2-14.0), respectively. CONCLUSION: ICIs administered before CT might enhance cytotoxic effects even in pts with immunorefractory MSS mCRC. The results of this small cohort need to be validated in independent prospective cohorts. The role of ICIs as modifiers of both tumour cells and microenvironment in mCRC deserves further research.
引用
- Martin-Romano P, Ammari S, El-Dakdoukti Y, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer. 2020. PMID: 32755794. doi:10.1016/j.ejca.2020.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。